A Study of ICP-022 in Patients With R/R DLBCL

Summary

It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There will be no control group in this study. Each subject will receive treatment orally every day in 28-day cycles. Each cycle starts immediately after the previously completed cycle without a break between cycles.

Timeline

Start

2020-05-07

Primary completion

2021-11-05

Completion

2021-12-13

Drugs

Indications